Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Histrelin (Supprelin LA / Vantas) vs Kisspeptin-10
An educational, source-based comparison of Histrelin (Supprelin LA / Vantas) and Kisspeptin-10 — how each peptide works, what it's researched for, and what to know before going deeper.
GnRH agonist implant for central precocious puberty and prostate cancer.
Synthetic nonapeptide GnRH agonist delivered via a subcutaneous hydrogel implant providing continuous release for 12 months, desensitizing the pituitary and suppressing sex steroids.
- Central precocious puberty (Supprelin LA)
- Advanced prostate cancer (Vantas)
- • FDA-approved.
- • Implant site reactions and rare implant breakage at removal.
A peptide product of the KISS1 gene that acts upstream of GnRH neurons via the KISS1R/GPR54 receptor. Research demonstrates robust LH (and indirectly testosterone/estradiol) responses without desensitizing the pituitary.
- Hypothalamic amenorrhea
- Male hypogonadism research
- IVF triggering protocols
- • Investigational; not FDA-approved.
- • Effects on the HPG axis warrant physician oversight.
Histrelin (Supprelin LA / Vantas) vs Kisspeptin-10 — Key differences
- Class: Histrelin (Supprelin LA / Vantas) is classified as GnRH Agonist · Endocrine, while Kisspeptin-10 is Hormonal · HPG Axis.
- Primary research focus: Histrelin (Supprelin LA / Vantas) — central precocious puberty (supprelin la); Kisspeptin-10 — hypothalamic amenorrhea.
- Tag: FDA-Approved · Endocrine vs Hormonal · HPG axis.